• Phytoestrogens and their effect on the health of women in the period of menopause (Literature review)
To content

Phytoestrogens and their effect on the health of women in the period of menopause (Literature review)

HEALTH OF WOMAN. 2017.10(126):128–132

Gordeeva G. D., Tovstanovskaya V. A., Ter-Tumasova A. G.
National Medical University named after А.А. Bogomolets, city of Kiev
Medical Center «HEALTHY AND HAPPY», Kiev

The article contains a review of the literature devoted to the problem of the effect of phytoestrogens (PE) on the health of a woman during menopause. The aspects of their mechanism of action are considered. Data on the effectiveness of the use of preparations containing PE in the complex treatment of climacteric disorders are given.
Key words: phytoestrogens, climacteric disorders in women.

REFERENCES

1. Akhtyamov SN. Getling ZM. Butov YuS. 2004. Stareniye kozhi. Eksperimentalnaya i klinicheskaya dermatokosmetologiya 5:2–10.

2. Baraboy VA. 2009. Izoflavony soi: biologicheskaya aktivnost i primeneniye. Biotekhnologiya 2;3:44–54.

3. Botoyeva EA. 2010. K voprosu o fitoestrogenakh. Byulleten VSNTs SO RAMN. 2(72):234–237.

4. Botoyeva EA. Ubeyeva IT. 2009. Biologicheskaya rol fitoestrogenov. Vestnik buryatskogo gosuniversiteta 12.

5. Bukharina E. 2007. Fitoestrogeny – mneniye ginekologa. J.Les Nouvelles Esthetic. 1:10–17.

6. Zdorovye zhenshchin i menopauza. Per. s angl. M. GEOTAR-MED. 2004:528.

7. Zotov OS, Postupalenko OV, Vereshchako RY. 2015. Fitoestroheny: molekuliarni mekhanizmy dii v onkolohichnomu aspekti. Klinichna endokrynolohiia ta endokrynna khirurhiia 3(51):7–16.

8. Kuznetsova IV. Uspenskaya YuB. 2013. Primeneniye fitoestrogenov u zhenshchin v period menopauzalnogo perekhoda i postmenopauze. Effektivnaya farmakoterapiya 6(55):44–51.

9. Maltseva LI. 2009. Fitoestrogeny soi v lechenii klimaktericheskogo sindroma. Prakticheskaya meditsina 2:119–121.

10. Margolina AA. Ernandes EI. 2001. Novaya kosmetologiya. M. Kosmetika i meditsina:204.

11. Mirzoyeva PN. Matushevskaya EV. Zaydiyeva YaZ. 2009. Topicheskiye fitoestrogeny v korrektsii involyutsionnykh izmeneniy kozhi. Vestn. dermatol. i venerol. 3:87–92.

12. Osteoporoz. Diagnostika. profilaktika i lecheniye. Klinicheskiye rekomendatsii. Pod red. Benevolenskoy LI. Lesnyak OM. M. GEOTAR-Media. 2010.

13. Smetnik VP. 2001. Biologiya i patobiologiya klimakteriya. V kn. «Rukovodstvo po klimakteriyu». M. MIA:9–35.

14. Smetnik VP. 2006. Alternativa zamestitelnoy gormonoterapii. V kn. «Meditsina klimakteriya». M. OOO Izd-vo Litera:166–86.

15. Smetnik VP. 2009. Prilivy: zagadka klimakteriya. Klimakteriy. Meditsinskiy nauchno-referativnyy zhurnal Rossiyskoy assotsiatsii po menopauze 1:3–4.

16. Smetnik VP. Ilina LM. 2009. Rol polovykh gormonov v razvitii metabolicheskikh rasstroystv u zhenshchin v peri- i ranney postmenopauze. Klimakteriy 1:8–13.

17. Tarumov RA. Grebenyuk AN. Basharin VA. Kovtun VYu. 2014. Biologicheskiye svoystva fitoestrogena genisteina. Meditsina ekstremalnykh situatsiy 2(48):55–68.

18. Tikhomirov AL. 2008. Izoflavony soi v lechenii klimaktericheskogo sindroma. Ginekologiya 2:44–46.

19. Turova EA. Korolevskaya LI. 2008. Izoflavony v korrektsii vozrastnykh izmeneniy kozhi. Ginekologiya 5:80–83.

20. Shishkova VN. 2013. Problemy stareniya i zamestitelnaya gormonalnaya terapiya u zhenshchin v postmenopauze. Rossiyskiy vestnik akushera-ginekologa 2:420–447.

21. Agnusdei D, Comston J. 2000. SERMs – A novel Option to Maintain Health in the Postmenopause. M. Dutitz. 161:21.

22. Atkinson C, Compston J, Day NE. 2004. The effects phytoestrogen isoflavones on bone density in women: a double-blind, randomized-controlled trial. Am J Clin Nutr. 79:326–333. https://doi.org/10.1093/ajcn/79.2.326; PMid:14749241

23. Bolanos R, Del Castillo A, Francia J. 2010. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause. 17;3:660–666. https://doi.org/10.1097/gme.0b013e3181cb4fb5

24. Brincat MP, Baron Y, Galea R. 2005. Estrogens and the skin. Am. Climacteric. 8:110–123. https://doi.org/10.1080/13697130500118100; PMid:16096167

25. Brown S, Rosen SJ. 2003. Osteoporosis. Med Clin North Am. 87:1039–1063. https://doi.org/10.1016/S0025-7125(03)00065-8

26. Brueggemeier RW, Gu X, Mobley JA et al. 2001. Effects of phytoestrogens and synthetic combinatorial libraries on aromatase, estrogen biosynthesis, and metabolism. Ann.N.Y. Acad.Sci. 948:51–66. https://doi.org/10.1111/j.1749-6632.2001.tb03986.x; PMid:11795395

27. Calleja-Agius J, Brincat MP. 2011. The effect of menopause on the skin and of the connective tiissues. Gynecol Endocrinol. 28(4):273–277. https://doi.org/10.3109/09513590.2011.613970; PMid:21970508

28. Calleja-Agius J, Muscat-Baron Y, Brincat MP. 2007. Skin ageing. Review Menopause International. 13:60–64. https://doi.org/10.1258/175404507780796325; PMid:17540135

29. Campbell MJ, Woodside JV, Honour JW et al. 2004. Effect of red clover-derived isoflavone supplementation on insulin-like growth factor, lipid and antioxidant status in healthy female volunteers: a pilot study. European J of Clinical Nutrition. 58:173–179. https://doi.org/10.1038/sj.ejcn.1601764; PMid:14679383

30. Chan MY, Wai Man G, Chen ZY et al. 2007. Oestrogen receptor alpha is required for biochanin A-induced apolipoprotein A-1 mRNA expression in HepG2 cells. Br. J. Nutr. 98;3:534–539. https://doi.org/10.1017/S0007114507750857; PMid:17532863

31. Chen YM, Ho SC, Lam SS et al. 2003. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J.Clin Endocrinol Metabol. 88:4740–4747. https://doi.org/10.1210/jc.2003-030290; PMid:14557449

32. Dai Q, Shu XO, Jin F. 2001. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer. 85:372–378. https://doi.org/10.1054/bjoc.2001.1873; PMid:11487268 PMCid:PMC2364075

33. Dechaud H, Ravard C, Claustrat F et al. 1999. Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG). Steroids. 64:328–34. https://doi.org/10.1016/S0039-128X(98)00114-7

34. Djuric Z, Chen G, Doenge DR et al. 2001. Effect of soy isoflavone supplementation on oxidative stress in men and women. Cancer Lett. 172:1–6. https://doi.org/10.1016/S0304-3835(01)00627-9

35. Fang M, Chen D, Sun Y et al. 2005. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta and MGMT genes by genistein and other isoflavones from soy. Clinical Cancer Research. 11:7033–7041. https://doi.org/10.1158/1078-0432.CCR-05-0406; PMid:16203797

36. Gencel VB, Benjamin MM, Bahou SN et al. 2012. Vascular effect of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease. Mini Rev. Med. Chem. 12(2):149–174. https://doi.org/10.2174/138955712798995020; PMid:22070687 PMCid:PMC3288319

37. Green RA. 1999. Measurement of estrogens effect on the brain using modern imaging techniques. Menopausal Med. 7:9–12.

38. Hill DA, Hill SR. 2010. Counseling patient about hormone therapy and alternatives for menopausal symptoms. Am. Fam. Physician. 82;7:801–807. PMid:20879703

39. Hillman GG et al. 2011. Soy isoflavones radio-sensitize lung cancer while mitigating normal tissue injury. Radiotherapy and Oncоlogy. 13;2:329–336. https://doi.org/10.1016/j.radonc.2011.10.020; PMid:22079530 PMCid:PMC3229191

40. Hwang J, Wang J, Morazzoni P et al. 2003. The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification. J.Biol.Med. 34:1271–1282. https://doi.org/10.1016/S0891-5849(03)00104-7

41. Jordan VC. 2001. The past, present and future of selective estrogen receptor modulation. New York Acad Sci. 949:72–79. https://doi.org/10.1111/j.1749-6632.2001.tb04004.x

42. Kaldas RS, Hughes GL. 2009. Reproductive and general effects of phytoestrogens in mammals. Reprod.Toxicol. Rev. 3:81–89. https://doi.org/10.1016/0890-6238(89)90042-7

43. Kritz-Silverstein D, Von Muhlen D, Barret-Connor E et al. 2003. Isoflavones and cognitive function in older women: the Soy and Postmenopausal Health In Aging (SOPHIA) Study. Menopause. 10:196–202. https://doi.org/10.1097/00042192-200310030-00004; PMid:12792289

44. Le Bail JC, Champavjer Y, Chulia AJ et al. 2000. Effects of phytoestrogens on aromatase, 3 beta and 17 beta-hydroxysteroid dehydrogenase activites and human breast cancer cells. Life Sci. 66:1282–1291. https://doi.org/10.1016/S0024-3205(00)00435-5

45. Li Z, Zhang Z, Hill D et al. 2005. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranscriptional levels. Cancer Research. 65;18:8200–8208. https://doi.org/10.1158/0008-5472.CAN-05-1302; PMid:16166295

46. Mahadi GB. 2005. Soy isoflavones cause endometrial hyperplasia? Nutr.Revs. 63:392–397. https://doi.org/10.1111/j.1753-4887.2005.tb00376.x

47. Markaverich BM. 2005. Effects of coumestrol on estrogen receptor function and uterine growth in ovariectomized rats. Environ. Helth Persр. 103:574–581. https://doi.org/10.1289/ehp.95103574

48. Milan MT, Dotlic J, Maricic S. 2009. Influence of red clover-derived isoflavones on serum lipid profile in postmenopausal women. J. Obstet. Gynaecol. Res. 35;6:1091–1095. https://doi.org/10.1111/j.1447-0756.2009.001059.x; PMid:20144173

49. Oseni T, Patel R, Pyle J et al. 2008. Selective estrogen receptor modulators and phytoestrogenes. Planta Med. 74;13:1656–1665. https://doi.org/10.1055/s-0028-1088304; PMid:18843590 PMCid:PMC2587438

50. Ohmichi M, Tasaka K, Kurachi H et al. 2005. Molecular mechanism of action of selective estrogen receptor modulator in target tissues. Endocr. J. 52;21:61–67. https://doi.org/10.1507/endocrj.52.161

51. Pietras RJ, Weinberg OK. 2005. Antiangiogenic steroids in human cancer therapy. Evidence-based Complementary and Alternative Medicine. 13;1:49–57. https://doi.org/10.1093/ecam/neh066; PMid:15841278 PMCid:PMC1062159

52. Pinell SR. 2003. Cutaneous photodamage, oxidative stress and topical antioxidant protection. J Am Acad Dermatol. 48;1:1–19. https://doi.org/10.1067/mjd.2003.16; PMid:12522365

53. Pines A. 2011. Vasomotor symptoms and cardiovascular disease risk. Climacteric. 14:535–536. https://doi.org/10.3109/13697137.2011.599058; PMid:21848496

54. Rice S, Whitehead SA. 2008. Phytoestrogens oestrogen synthesis and breast cancer. J. Steroid. Biochem. Mol. Biol. 108:186–195. https://doi.org/10.1016/j.jsbmb.2007.09.003; PMid:17936616

55. Rice S, Mason HD, Whitehead SA. 2006. Phytoestrogens and their low dose combinations inhibit mRNA exspression and activity of aromatase in human granulosa-luteal cells. J. Steroid Biochem Mol Biol. 101(4–5):216–225. https://doi.org/10.1016/j.jsbmb.2006.06.021; PMid:16965912

56. Rissman EF. 2006. Roles of oestrogen receptors alpha and beta in behavioural neuroendocrinology. J. Neuroendocrinol. 20:873–879. https://doi.org/10.1111/j.1365-2826.2008.01738.x; PMid:18601711 PMCid:PMC2667101

57. Robb EL, Page MM, Wiens BE et al. 2008. Molecular mechanisms of oxidative stress resistance induced by resveratrol: specific and progressive induction of MnSOD. Biochem.Biophys. Res. Commun. 367:406–417. https://doi.org/10.1016/j.bbrc.2007.12.138; PMid:18167310

58. Rimbach G, Boesch-Saadatmandi C, Frank J. 2008. Dietary isoflavones in the prevention of cardiovascular disease – a molecular perspective. Food. Chem. Toxicol. 46:1308–1319. https://doi.org/10.1016/j.fct.2007.06.029; PMid:17689850

59. Roussow JE, Anderson GL, Prentice RL. 2002. Writing group for the womens health initiative investigators. Risks and benefits of estrogen + progestin in healthy postmenopausal women. JAMA. 228:321–333.

60. Shutt DA. 2006. The effect of plant oestrogens on animal reproduction. Endeavor. 35:110–113. https://doi.org/10.1016/0160-9327(76)90004-1

61. Simoncini T, Fomari L, Mannella P. 2005. Activation of nutric oxide synthesis in human endothelial cells by red clover extracts. Menopause. 12;1:69–77. https://doi.org/10.1097/00042192-200512010-00013

62. Taku K, Melby MK, Kronenberg F et al. 2012. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and metа-analysis of randomized controlled trials. Menopause. 19;7:776–790. https://doi.org/10.1097/gme.0b013e3182410159; PMid:22433977

63. Tempfer CB, Bentz EK, Leodolter S et al. 2007. Phytoestrogens in clinical practice: a review of the literature. Fertil. Steril. 87;6:1243–1249. https://doi.org/10.1016/j.fertnstert.2007.01.120; PMid:17490659

64. Tsai SA, Stefanick ML, Stafford RS. 2011. Trends in menopausal hormone therapy use of US office-based physicians 2000–2009. Menopause. 18;4:385–392. https://doi.org/10.1097/gme.0b013e3181f43404; PMid:21127439 PMCid:PMC3123410

65. Verdier-Servrain S, Bonter F, Gilchrest B. 2006. Bioligy of estrogens in skin: implications for skin aging. Experimental Dermatology. 15:83–94. https://doi.org/10.1111/j.1600-0625.2005.00377.x; PMid:16433679

66. Walker SE, Register TS, Appt SE et al. 2008. Plasma lipid-dependent and –independent effects of dietary soy protein and social status on atherogenesis in premenopausal monkeys: implications for postmenopausal atherosclerosis burden. Menopause. 15(4):256–263. https://doi.org/10.1097/gme.0b013e3181612cef

67. Warri A, Saarinen N, Makela S, Hilakivi-Clarke L. 2008. The role of early life genistein exposures in modifying breast cancer risk. Br.J.Cancer. 98:1485–1493. https://doi.org/10.1038/sj.bjc.6604321; PMid:18392054 PMCid:PMC2391102

68. Witztum JL, Steinberg D. 2001. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc. Med. 11:93–102. https://doi.org/10.1016/S1050-1738(01)00111-6

69. Whitten PL, Russel E, Naftolin F. 2002. Effects of normal, human-concentration, phytoestrogen diet on rat uterine growth. Steroids. 57:98–102. https://doi.org/10.1016/0039-128X(92)90066-I

70. Xiao CW. 2008. Health effect of soy protein and isoflavones in humans. J.Nutr. 138:1244–1249. https://doi.org/10.1093/jn/138.6.1244S